Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells

Open access

Abstract

The anti-apoptotic BCL-2 proteins (BCL-2, BCL-XL, MCL-1, A1, BCL-W) counteract apoptotic signals emerging during development and under stress conditions, and are thus essential for the survival of every cell. While the “BCL-2 addiction” of different cell types is well described in mouse models, there is only limited information available on the role of different anti-apoptotic BCL-2 proteins in a given human cell type. Here we characterize the role of BCL-XL for survival and function of human hematopoietic cells, with the aim to predict hematological side effects of novel BCL-XL-inhibiting BH3-mimetics and to identify hematological malignancies potentially responsive to such inhibitors. Earlier clinical studies have shown that the combined BCL-2/BCL-XL/BCL-W inhibitor, Navitoclax (ABT-263) induces severe thrombocytopenia caused by direct platelet demise and counteracted by increased megakaryopoiesis. In contrast, murine studies have reported important contribution of BCL-XL to survival of late erythroid cells and megakaryocytes. Using lentiviral knockdown, we show that the roles of BCL-XL for human hematopoietic cells are much more pronounced than expected from murine data and clinical trials. Efficient genetic or chemical BCL-XL inhibition resulted in significant loss of human erythroid cells beginning from very early stages of erythropoiesis, and in a reduction of megakaryocytes. Most importantly, BCL-XL deficient human hematopoietic stem cells and multipotent progenitors were reduced in numbers, and they showed a severely impaired capacity to engraft in mice during xenotransplantation. BCL-XL deficiency was fully compensated by BCL-2 overexpression, however, loss of its antagonist BIM did not result in any rescue of human erythroid or stem and progenitor cells. We thus conclude that novel and specific BCL-XL inhibitors might be efficient to treat malignancies of erythroid or megakaryocytic origin, such as polycythemia vera, acute erythroid leukemia, essential thrombocytosis or acute megakaryocytic leukemia. At the same time, it can be expected that they will have more severe hematological side effects than Navitoclax.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-019-2203-z

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BCL-XL inhibition sensitizes human HSPCs to certain cytotoxic drugs. a, b Human CD34+ cells were transfected with lentiviral vectors targeting Luciferase (shLuci) or human BCL-XL (shBCL-XL). Knockdown efficiency of shBCL-XL was determined by qRT-PCR; mRNA expression was normalized to 18S. Bars represent mean ± SEM; n = 4 from four independent experiments; p = 0.0286 (a). In addition, protein levels were determined in CD34+GFP+ cells (b). c Apoptosis was determined in lentivirally transduced cells 24 h after end of viral transduction. d Lentivirally transduced CD34+ cells were subjected to cytotoxic treatment for 24 h; Control (Co, with serum), Serum deprivation (Serum depr.), 0.5 µg/ml VP16 (Etoposide), 0.05 µg/ml Taxol, 1 µg/ml Tunicamycin (Tu), 1 µM Staurosporine (Stau), 5 µM ABT-737. Cells were stained with Annexin V and 7-AAD and GFP+ cells were analyzed for percentage specific apoptosis by flow cytometry. Bars represent mean ± SEM, n = 4 from two independent experiments. The Mann–Whitney test was performed; p = 0.0286 for Tu and Stau.
Fig. 1 BCL-XL inhibition sensitizes human HSPCs to certain cytotoxic drugs. a, b Human CD34+ cells were transfected with lentiviral vectors targeting Luciferase (shLuci) or human BCL-XL (shBCL-XL). Knockdown efficiency of shBCL-XL was determined by qRT-PCR; mRNA expression was normalized to 18S. Bars represent mean ± SEM; n = 4 from four independent experiments; p = 0.0286 (a). In addition, protein levels were determined in CD34+GFP+ cells (b). c Apoptosis was determined in lentivirally transduced cells 24 h after end of viral transduction. d Lentivirally transduced CD34+ cells were subjected to cytotoxic treatment for 24 h; Control (Co, with serum), Serum deprivation (Serum depr.), 0.5 µg/ml VP16 (Etoposide), 0.05 µg/ml Taxol, 1 µg/ml Tunicamycin (Tu), 1 µM Staurosporine (Stau), 5 µM ABT-737. Cells were stained with Annexin V and 7-AAD and GFP+ cells were analyzed for percentage specific apoptosis by flow cytometry. Bars represent mean ± SEM, n = 4 from two independent experiments. The Mann–Whitney test was performed; p = 0.0286 for Tu and Stau.CC BY · PubMed Central
Fig. 2 BCL-XL is important for the survival of differentiating CD34+ cells. a–f Human HSPC were seeded in MethoCult medium. After 10 days of culture, colonies were identified (granulocyte-erythrocyte-megakaryocyte-monocyte precursors (GEMM), granulocytic–monocytic precursors (GM), granulocytes (G), erythroid (E), and monocyte precursors (M)) and counted by light microscopy (a). GFP expression was determined before and after culture (b). Several hematopoietic populations were analyzed by flow cytometry along with GFP expression (c, d) and cell numbers (e, f). Supplementary Table 2 shows the immunophenotype of the hematopoietic populations. Abbreviations: hematopoietic stem cells (HSC), multipotent progenitors (MPP), granulocytic–monocytic progenitors (GM), Colony Forming Unit granulocytes (CFU-G). Bars represent mean ± SEM, n = 8–9 from five independent experiments. p-values: b ****p < 0.0001. c **p = 0.0025, ***p = 0.001, ****p < 0.0001. d ****p < 0.0001. e *p = 0.036 for CD34+ cells, *p = 0.0274 for HSC. f **p = 0.0037.
Fig. 2 BCL-XL is important for the survival of differentiating CD34+ cells. a–f Human HSPC were seeded in MethoCult medium. After 10 days of culture, colonies were identified (granulocyte-erythrocyte-megakaryocyte-monocyte precursors (GEMM), granulocytic–monocytic precursors (GM), granulocytes (G), erythroid (E), and monocyte precursors (M)) and counted by light microscopy (a). GFP expression was determined before and after culture (b). Several hematopoietic populations were analyzed by flow cytometry along with GFP expression (c, d) and cell numbers (e, f). Supplementary Table 2 shows the immunophenotype of the hematopoietic populations. Abbreviations: hematopoietic stem cells (HSC), multipotent progenitors (MPP), granulocytic–monocytic progenitors (GM), Colony Forming Unit granulocytes (CFU-G). Bars represent mean ± SEM, n = 8–9 from five independent experiments. p-values: b ****p < 0.0001. c **p = 0.0025, ***p = 0.001, ****p < 0.0001. d ****p < 0.0001. e *p = 0.036 for CD34+ cells, *p = 0.0274 for HSC. f **p = 0.0037.CC BY · PubMed Central
Fig. 3 BCL-XL is essential for human erythropoiesis from very early stages. a–f Human HSPC were cultured in Human Erythroid Massive Amplification assay (HEMA) to study the impact of BCL-XL knockdown on different erythroid progenitors in vitro. Different populations were analyzed via flow cytometry at indicated time points of culture. Left panels show the stages of erythroid differentiation (a, c, e), the right panels show GFP+ cells in the individual subpopulations (b, d, f). Bars represent mean ± SEM, n = 5 from five independent experiments. p-values: b, f **p = 0.0079.
Fig. 3 BCL-XL is essential for human erythropoiesis from very early stages. a–f Human HSPC were cultured in Human Erythroid Massive Amplification assay (HEMA) to study the impact of BCL-XL knockdown on different erythroid progenitors in vitro. Different populations were analyzed via flow cytometry at indicated time points of culture. Left panels show the stages of erythroid differentiation (a, c, e), the right panels show GFP+ cells in the individual subpopulations (b, d, f). Bars represent mean ± SEM, n = 5 from five independent experiments. p-values: b, f **p = 0.0079.CC BY · PubMed Central
Fig. 4 Treatment with A-1155463 confirms the detrimental effects of BCL-XL inhibition on erythroid cells and CD34+ 38− stem and progenitor cells. a Freshly isolated CD34+ and CD34− cells were treated with the indicated concentrations of the BCL-XL inhibitor A-1155463. After 24 h apoptosis was measured by flow cytometry and percentage specific apoptosis was determined (n = 4–5). b–f Human HSPC were differentiated in Methocult® culture in the presence of 0.5 and 1.5 µM of the inhibitor. After 11 days, total colony numbers (b) as well as total cell numbers (c) were determined (n = 4) and immature (d), erythroid (e), and myeloid cell populations (f) were analyzed by flow cytometry. g–i CD34+ cells were differentiated in the absence of the inhibitor for 11 days, and their progenies were isolated and treated with A-1155463 for 24 h. Immature (g), erythroid (h), and myeloid cell populations (i) were analyzed by flow cytometry. Abbreviations: granulocytic–monocytic progenitors (GM), colony forming unit monocytes (CFU-M). Bars represent mean ± SEM, n = 2–3. p-values: (d, e) *p = 0.0286.
Fig. 4 Treatment with A-1155463 confirms the detrimental effects of BCL-XL inhibition on erythroid cells and CD34+ 38− stem and progenitor cells. a Freshly isolated CD34+ and CD34− cells were treated with the indicated concentrations of the BCL-XL inhibitor A-1155463. After 24 h apoptosis was measured by flow cytometry and percentage specific apoptosis was determined (n = 4–5). b–f Human HSPC were differentiated in Methocult® culture in the presence of 0.5 and 1.5 µM of the inhibitor. After 11 days, total colony numbers (b) as well as total cell numbers (c) were determined (n = 4) and immature (d), erythroid (e), and myeloid cell populations (f) were analyzed by flow cytometry. g–i CD34+ cells were differentiated in the absence of the inhibitor for 11 days, and their progenies were isolated and treated with A-1155463 for 24 h. Immature (g), erythroid (h), and myeloid cell populations (i) were analyzed by flow cytometry. Abbreviations: granulocytic–monocytic progenitors (GM), colony forming unit monocytes (CFU-M). Bars represent mean ± SEM, n = 2–3. p-values: (d, e) *p = 0.0286.CC BY · PubMed Central
Fig. 5 Human cells lacking BCL-XL show poor engraftment in xenograft mice. a–d Lentivirally transduced or untransduced human HSPC were transplanted in Rag2−/−γc−/− mice after sub-lethal irradiation. Mice were sacrificed 7–8 weeks after transplantation and bone marrow (BM) and spleen were analyzed for the presence of various human hematopoietic populations by flow cytometry (a, b) as well as for GFP expression in the individual subpopulations (c, d). Bars represent mean ± SEM, n = 6-10 from six independent experiments. p-values: b **p = 0.0047 for control vs shBCL-XL CD33+ cells; **p = 0.003 for shLuci vs shBCL-XL CD33+ cells; *p = 0.035 control vs shBCL-XL CD19+IgM− cells; *p = 0.0431 for control vs shLuci CD19+IgM+ cells; *p = 0.014 for control vs shBCL-XL CD19+IgM+ cells (c) **p = 0.0017, *p = 0.0312 (d) **p = 0.0017 for CD34+ and CD19−10+ cells; ***p = 0.001; **p = 0.003 for CD19+IgM−, and CD19+IgM+ cells.
Fig. 5 Human cells lacking BCL-XL show poor engraftment in xenograft mice. a–d Lentivirally transduced or untransduced human HSPC were transplanted in Rag2−/−γc−/− mice after sub-lethal irradiation. Mice were sacrificed 7–8 weeks after transplantation and bone marrow (BM) and spleen were analyzed for the presence of various human hematopoietic populations by flow cytometry (a, b) as well as for GFP expression in the individual subpopulations (c, d). Bars represent mean ± SEM, n = 6-10 from six independent experiments. p-values: b **p = 0.0047 for control vs shBCL-XL CD33+ cells; **p = 0.003 for shLuci vs shBCL-XL CD33+ cells; *p = 0.035 control vs shBCL-XL CD19+IgM− cells; *p = 0.0431 for control vs shLuci CD19+IgM+ cells; *p = 0.014 for control vs shBCL-XL CD19+IgM+ cells (c) **p = 0.0017, *p = 0.0312 (d) **p = 0.0017 for CD34+ and CD19−10+ cells; ***p = 0.001; **p = 0.003 for CD19+IgM−, and CD19+IgM+ cells.CC BY · PubMed Central
Fig. 6 BCL-2 overexpression reverses all effects of BCL-XL deficiency. a–f Human CD34+ HSPC were lentivirally transduced with one or two lentiviruses as indicated; pLeGO-iG empty vector with GFP (IG-G); pLeGO-iG BCL-2 overexpressing vector with GFP (BCL2-G); pLeGOhU6 with shLuci and dTomato (shLuci-T); pLeGOhU6 with shBCL-XL and dTomato (shBCL-XL-T); pLeGOhU6 with shLuci and dTomato + pLeGO-iG empty vector with GFP (shLuci-T IG-G); pLeGOhU6 with shLuci and dTomato + pLeGO-iG BCL-2 overexpressing vector with GFP (shLuci-T BCL2-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGO-iG empty vector with GFP (shBCL-XL-T IG-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGO-iG BCL-2 overexpressing vector with GFP (shBCL-XL-T BCL2-G) (a) and cultured for 8 days under HEMA culture conditions (b–d) or in MethoCult plates (e, f). Bars represent percentage GFP+, percentage Tomato+, percentage double-negative, and percentage double-positive cells (mean ± SEM), n = 4–8 from four independent experiments.
Fig. 6 BCL-2 overexpression reverses all effects of BCL-XL deficiency. a–f Human CD34+ HSPC were lentivirally transduced with one or two lentiviruses as indicated; pLeGO-iG empty vector with GFP (IG-G); pLeGO-iG BCL-2 overexpressing vector with GFP (BCL2-G); pLeGOhU6 with shLuci and dTomato (shLuci-T); pLeGOhU6 with shBCL-XL and dTomato (shBCL-XL-T); pLeGOhU6 with shLuci and dTomato + pLeGO-iG empty vector with GFP (shLuci-T IG-G); pLeGOhU6 with shLuci and dTomato + pLeGO-iG BCL-2 overexpressing vector with GFP (shLuci-T BCL2-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGO-iG empty vector with GFP (shBCL-XL-T IG-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGO-iG BCL-2 overexpressing vector with GFP (shBCL-XL-T BCL2-G) (a) and cultured for 8 days under HEMA culture conditions (b–d) or in MethoCult plates (e, f). Bars represent percentage GFP+, percentage Tomato+, percentage double-negative, and percentage double-positive cells (mean ± SEM), n = 4–8 from four independent experiments.CC BY · PubMed Central
Fig. 7 BIM knockdown does not rescue BCL-XL deficient erythroid cells. a–f Human CD34+ HSPC were lentivirally transduced as indicated; pLeGOhU6 with shLuci and GFP (shLuci-G); pLeGOhU6 with shBIM and GFP (shBIM-G); pLeGOhU6 with shLuci and dTomato (shLuci-T); pLeGOhU6 with shBCL-XL and dTomato (shBCL-XL-T); pLeGOhU6 with shLuci and dTomato + pLeGOhU6 with shLuci and GFP (shLuci-T shLuci-G); pLeGOhU6 with shLuci and dTomato + pLeGOhU6 with shBIM and GFP (shLuci-T shBIM-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGOhU6 with shLuci and GFP (shBCL-XL-T shLuci-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGOhU6 with shBIM and GFP (shBCL-XL-T shBIM-G), and transduction efficiency was determined after 48 h, n = 1 (CD34+ cells from two cord bloods) (a). MethoCult experiments (b, c) as well as an 8-day long HEMA culture (d, e) were performed (n = 2 from one independent experiment). In addition, erythroid cells transduced with shBCL-XL (dTomato) and shBIM (GFP) were cultured for 8 days with 10-fold concentrations of EPO and/or SCF (f) CD117+CD71+CD235a+ and CD117−CD71+CD235a+ cells.
Fig. 7 BIM knockdown does not rescue BCL-XL deficient erythroid cells. a–f Human CD34+ HSPC were lentivirally transduced as indicated; pLeGOhU6 with shLuci and GFP (shLuci-G); pLeGOhU6 with shBIM and GFP (shBIM-G); pLeGOhU6 with shLuci and dTomato (shLuci-T); pLeGOhU6 with shBCL-XL and dTomato (shBCL-XL-T); pLeGOhU6 with shLuci and dTomato + pLeGOhU6 with shLuci and GFP (shLuci-T shLuci-G); pLeGOhU6 with shLuci and dTomato + pLeGOhU6 with shBIM and GFP (shLuci-T shBIM-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGOhU6 with shLuci and GFP (shBCL-XL-T shLuci-G); pLeGOhU6 with shBCL-XL and dTomato + pLeGOhU6 with shBIM and GFP (shBCL-XL-T shBIM-G), and transduction efficiency was determined after 48 h, n = 1 (CD34+ cells from two cord bloods) (a). MethoCult experiments (b, c) as well as an 8-day long HEMA culture (d, e) were performed (n = 2 from one independent experiment). In addition, erythroid cells transduced with shBCL-XL (dTomato) and shBIM (GFP) were cultured for 8 days with 10-fold concentrations of EPO and/or SCF (f) CD117+CD71+CD235a+ and CD117−CD71+CD235a+ cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 55

Metadata

Authors
Afreen, S., Bohler, S., Müller, A., Demmerath, E.-M., Weiss, J. M., Jutzi, J. S., Schachtrup, K., Kunze, M., & Erlacher, M.
Affiliations
University of Freiburg (DE)
Corresponding author
Erlacher, Miriam
Venue
Cell Death & Disease
Published
2020-01-06
Volume
11
Issue
1
Pages
8-8
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2997600890
Cited by
55
References
53
Citations by year
2026: 4 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 8 · 2020: 3
FWCI
2.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • European Hematology Association (TRTH112)
  • Deutscher Akademischer Austauschdienst (57048249)
  • Deutsche Forschungsgemeinschaft (FOR‐2036, DFG FOR 2036, ER599/3-2)
  • H2020 European Research Council (638145)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
Bcl-xL, erythropoiesis, hematopoietic engraftment, Bcl-2 family proteins, apoptosis, Bcl-xL inhibitors, BH3 mimetics, navitoclax, thrombocytopenia, megakaryocytes, Bcl-2, building information modeling, multipotent progenitors, polycythemia vera, acute megakaryoblastic leukemia, hematological side effects
MeSH terms
Bcl-2-Like Protein 11, Animals, Erythropoiesis, Hematopoietic Stem Cells, Humans, Isoquinolines, Transplantation, Heterologous, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Erythroid Cells, bcl-X Protein, Mice, Benzothiazoles, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. https://app.cochat.ai/papers/10.1038/s41419-019-2203-z
The paper
Afreen, S., Bohler, S., Müller, A., Demmerath, E.-M., Weiss, J. M., Jutzi, J. S., Schachtrup, K., Kunze, M., & Erlacher, M. (2020). BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. Cell Death & Disease. https://doi.org/10.1038/s41419-019-2203-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.